PHAS Stock Overview
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases.
PhaseBio Pharmaceuticals, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.25|
|52 Week High||US$4.10|
|52 Week Low||US$0.50|
|1 Month Change||26.92%|
|3 Month Change||38.11%|
|1 Year Change||-60.19%|
|3 Year Change||-83.29%|
|5 Year Change||n/a|
|Change since IPO||-75.00%|
Recent News & Updates
PhaseBio Pharmaceuticals GAAP EPS of -$0.34 misses by $0.03, revenue of $0.21M misses by $0.29M
PhaseBio Pharmaceuticals press release (NASDAQ:PHAS): Q2 GAAP EPS of -$0.34 misses by $0.03. Revenue of $0.21M (-98.0% Y/Y) misses by $0.29M. Shares -0.86% PM.
|PHAS||US Biotechs||US Market|
Return vs Industry: PHAS underperformed the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: PHAS underperformed the US Market which returned -10.2% over the past year.
|PHAS Average Weekly Movement||20.2%|
|Biotechs Industry Average Movement||12.6%|
|Market Average Movement||7.7%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: PHAS is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 20% a week.
Volatility Over Time: PHAS's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension.
PhaseBio Pharmaceuticals, Inc. Fundamentals Summary
|PHAS fundamental statistics|
Is PHAS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PHAS income statement (TTM)|
|Cost of Revenue||US$87.70m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.06|
|Net Profit Margin||-12,572.13%|
How did PHAS perform over the long term?See historical performance and comparison